Las hormonas GLP-1, amilina y glucagn tambin se descontrolan, lo que dificulta el control del hambre y la glucosa
Moreover, given that there are now millions of patient-years of clinical experience with DPP-4 inhibitors since they were given regulatory approval in 2006, their benign, placebo-like side effect profile (39) also suggests that the number of physiologically relevant substrates is likely to be limited
One obvious impact of consumers using GLP-1 is that they eat and spend less: grocery spending declines of about 6% for the general population and of 9% for the high-end consumers, which are the ones that brands tend to focus on
2) compared to products from STR 5,6,7,8,22
Co-authors with Wong on this paper included Hridhay Karthikeyan, MS and Wenjun Fan, MD, MS, PhD, also with UC Irvine